NASDAQ:EXAS Exact Sciences (EXAS) Stock Forecast, Price & News $65.94 -0.91 (-1.36%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$65.73▼$67.3550-Day Range$65.94▼$99.0452-Week Range$29.27▼$100.77Volume1.52 million shsAverage Volume1.93 million shsMarket Capitalization$11.91 billionP/E RatioN/ADividend YieldN/APrice Target$97.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exact Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside47.1% Upside$97.00 Price TargetShort InterestBearish4.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment1.38Based on 4 Articles This WeekInsider TradingSelling Shares$2.94 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.90) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector111th out of 962 stocksMedical Laboratories Industry4th out of 23 stocks 4.3 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $97.00, Exact Sciences has a forecasted upside of 47.1% from its current price of $65.94.Amount of Analyst CoverageExact Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.73% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Exact Sciences has recently increased by 1.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 3.0 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search InterestOnly 12 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat Follows11 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,944,657.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions89.13% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($1.90) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -27.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -27.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exact Sciences (NASDAQ:EXAS) StockExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 14, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and GoodRx Holdings (GDRX)September 25, 2023 | Altimetry (Ad)WARNING: Seven millionaires to trigger sudden market panic?The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.September 7, 2023 | forbes.comExact SciencesAugust 31, 2023 | finance.yahoo.comExact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCHAugust 31, 2023 | msn.comExact Sciences (EXAS) Price Target Increased by 5.70% to 112.25August 30, 2023 | finance.yahoo.comExact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical TrialsAugust 28, 2023 | finance.yahoo.comExact Sciences Corporation (EXAS) Rallied on Reporting Strong ResultsSeptember 25, 2023 | Altimetry (Ad)WARNING: Seven millionaires to trigger sudden market panic?The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.August 21, 2023 | finance.yahoo.comNot a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer ScreeningsAugust 18, 2023 | markets.businessinsider.comCiti Sticks to Its Buy Rating for Exact Sciences (EXAS)August 16, 2023 | seekingalpha.comExact Sciences: Adjusting My Strategy After Encouraging Q2 EarningsAugust 9, 2023 | msn.comPiper Sandler Maintains Exact Sciences (EXAS) Neutral RecommendationAugust 4, 2023 | msn.comJefferies Maintains Exact Sciences (EXAS) Buy RecommendationAugust 4, 2023 | msn.comExact Sciences, A Cathie Wood Darling, Skids Despite A Sixth Big QuarterAugust 3, 2023 | fool.comWhy Shares of Exact Sciences Corporation Are Down This WeekAugust 3, 2023 | msn.comBenchmark cuts Exact Sciences to hold, citing valuationAugust 3, 2023 | msn.comBenchmark Downgrades Exact Sciences (EXAS)August 3, 2023 | finance.yahoo.comWhy Exact Sciences Stock Slumped WednesdayAugust 3, 2023 | finance.yahoo.comAll Major Indexes Post Losses As Nasdaq Loses Over 2%; This Networking Stock Pops To Buck The TrendAugust 2, 2023 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call TranscriptAugust 2, 2023 | markets.businessinsider.comExact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited GrowthAugust 2, 2023 | finance.yahoo.comStock Market Spooked By Fitch Downgrade, But ELF Beauty SoarsAugust 2, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Exact Sciences (EXAS)August 1, 2023 | msn.comHere's What Key Metrics Tell Us About Exact Sciences (EXAS) Q2 EarningsAugust 1, 2023 | finance.yahoo.comExact Sciences (EXAS) Q2 2023 Earnings Call TranscriptAugust 1, 2023 | finance.yahoo.comExact Sciences Announces Second-Quarter 2023 ResultsSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Company Calendar Last Earnings8/01/2023Today9/25/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,400Year Founded1995Price Target and Rating Average Stock Price Forecast$97.00 High Stock Price Forecast$130.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside+47.1%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-623,510,000.00 Net Margins-18.76% Pretax Margin-18.87% Return on Equity-14.08% Return on Assets-6.85% Debt Debt-to-Equity Ratio0.76 Current Ratio2.41 Quick Ratio2.14 Sales & Book Value Annual Sales$2.08 billion Price / Sales5.72 Cash FlowN/A Price / Cash FlowN/A Book Value$17.13 per share Price / Book3.85Miscellaneous Outstanding Shares180,660,000Free Float178,316,000Market Cap$11.91 billion OptionableOptionable Beta1.41 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 57)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 45)Exec. VP & CFO Comp: $518.13kMs. Sarah Condella (Age 42)Exec. VP of HR Comp: $742.76kMr. Everett V. Cunningham (Age 57)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 51)Chief Science Officer Ms. Megan JonesAssociate Mang. of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 43)Sr. VP, Gen. Counsel & Sec. Mr. Vic ParkerHead of SalesMs. Kristen WeilerVP of MarketingMore ExecutivesKey CompetitorsQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHNateraNASDAQ:NTRARevvityNYSE:RVTYFresenius Medical Care AG & Co. KGaANYSE:FMSView All CompetitorsInsiders & InstitutionsFarther Finance Advisors LLCBought 256 shares on 9/12/2023Ownership: 0.000%ST Germain D J Co. Inc.Bought 495 shares on 9/7/2023Ownership: 0.000%Arlington Capital Management Inc.Bought 6,881 shares on 8/24/2023Ownership: 0.010%Wolverine Trading LLCBought 9,100 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 2,127 shares on 8/21/2023Ownership: 0.158%View All Insider TransactionsView All Institutional Transactions EXAS Stock - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price forecast for 2023? 14 equities research analysts have issued 1 year price objectives for Exact Sciences' shares. Their EXAS share price forecasts range from $60.00 to $130.00. On average, they anticipate the company's stock price to reach $97.00 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2023? Exact Sciences' stock was trading at $49.51 on January 1st, 2023. Since then, EXAS shares have increased by 33.2% and is now trading at $65.94. View the best growth stocks for 2023 here. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) issued its earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05. The medical research company earned $622.10 million during the quarter, compared to analyst estimates of $601.14 million. Exact Sciences had a negative trailing twelve-month return on equity of 14.08% and a negative net margin of 18.76%. The business's revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.94) earnings per share. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Principal Healthcare Innovators ETF (BTEC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT) and VanEck Biotech ETF (BBH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2023 earnings guidance on Wednesday, June, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). What is Exact Sciences' stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS." Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (3.96%), Capital World Investors (3.76%), Baillie Gifford & Co. (2.53%), Artisan Partners Limited Partnership (1.96%), Geode Capital Management LLC (1.49%) and Sumitomo Mitsui Trust Holdings Inc. (1.47%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy and Sarah Condella. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exact Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $65.94. How much money does Exact Sciences make? Exact Sciences (NASDAQ:EXAS) has a market capitalization of $11.91 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. How many employees does Exact Sciences have? The company employs 6,400 workers across the globe. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More How can I contact Exact Sciences? Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701. This page (NASDAQ:EXAS) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.